Kidney in early atherosclerosis

被引:154
作者
Chade, AR
Lerman, A
Lerman, LO [1 ]
机构
[1] Mayo Clin, Coll Med, Div Nephrol & Hypertens, Dept Internal Med, Rochester, MN 55905 USA
[2] Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA
关键词
kidney; atherosclerosis; oxidative stress; fibrosis;
D O I
10.1161/01.HYP.0000167121.14254.a0
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Atherosclerosis represents one of the major causes of premature death in the United States today, and it is frequently associated with, exacerbates, and is aggravated by chronic kidney disease (CKD). Atherosclerosis integrates the response to a number of insults, and consequently, the accelerated atherosclerosis found in CKD patients is associated with activation of a variety of humoral and tissue mechanisms. Hypertension, diabetes, dyslipidemia, obesity, metabolic syndrome, and additional nontraditional risk factors can damage the kidney directly and by promoting intrarenal atherogenesis, even in the absence of obstructive lesions in the renal artery. Evidence indicates that increased oxidative stress and inflammation may mediate a large part of the effects of risk factors on the kidney. In turn, progressive deterioration of renal function in CKD may lead to dyslipidemia or accumulation of uremic toxins, which can induce production of free radicals and activate proinflammatory and fibrogenic factors, leading to vascular endothelial cell dysfunction and injury, and favoring development of atherosclerosis. Therefore, the kidney can be a villain or a victim during atherogenesis. The purpose of this review is to provide new insights into the mechanisms by which atherogenic factors may instigate early renal injury.
引用
收藏
页码:1042 / 1049
页数:8
相关论文
共 110 条
[1]   Cellular lipid metabolism and the role of lipids in progressive renal disease [J].
Abrass, CK .
AMERICAN JOURNAL OF NEPHROLOGY, 2004, 24 (01) :46-53
[2]  
Amann K, 2003, CLIN NEPHROL, V60, pS13
[3]   Effect of antioxidant therapy with dl-α-tocopherol on cardiovascular structure in experimental renal failure [J].
Amann, K ;
Törnig, J ;
Buzello, M ;
Kuhlmann, A ;
Gross, ML ;
Adamczak, M ;
Buzello, M ;
Ritz, E .
KIDNEY INTERNATIONAL, 2002, 62 (03) :877-884
[4]   Decreased inducibility of TNF expression in lipid-loaded macrophages [J].
Ares M.P.S. ;
Stollenwerk M. ;
Olsson A. ;
Kallin B. ;
Jovinge S. ;
Nilsson J. .
BMC Immunology, 3 (1)
[5]   End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? [J].
Arici, M ;
Walls, J .
KIDNEY INTERNATIONAL, 2001, 59 (02) :407-414
[6]  
Baggio B, 2001, J NEPHROL, V14, P286
[7]   Influence of atherosclerosis on age-related changes in renal size and function [J].
Bax, L ;
van der Graaf, Y ;
Rabelink, AJ ;
Algra, A ;
Beutler, JJ ;
Mali, WPTM .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2003, 33 (01) :34-40
[8]  
Becker BN, 1998, EXP NEPHROL, V6, P57
[9]   Enhanced renal cortical vascularization in experimental hypercholesterolemia [J].
Bentley, MD ;
Rodriguez-Porcel, M ;
Lerman, A ;
Sarafov, MH ;
Romero, JC ;
Pelaez, LI ;
Grande, JP ;
Ritman, EL ;
Lerman, LO .
KIDNEY INTERNATIONAL, 2002, 61 (03) :1056-1063
[10]  
BRENNER B, 1976, KIDNEY, V2